辛伐他汀和普伐他汀对冠心病sVCAM-1水平的影响

Effects of simvastatin and pravastatin on the levels of soluble vascular cell adhesion molecule-1 in patients with coronary heart disease

目的 探讨辛伐他汀和普伐他汀对冠心病 (CHD)患者血清中可溶性血管细胞粘附分子 1(sVCAM 1)水平的影响。 方法 10 6例CHD患者随机分为 3组 :A组 (安慰剂组 ) ,B组 (辛伐他汀组 ) ,C组 (普伐他汀组 )。采用酶联免疫吸附法 (ELISA)和常规酶法分别测定 3组患者用药前与用药 4、6周和 8周后血清sVCAM 1含量及总胆固醇 (TC)水平。 结果 ①B组和C组患者服药 4、6周及 8周后血清sVCAM 1含量明显低于A组 (P <0 0 5 ,P <0 0 1,P <0 0 1)。②B组和C组患者服药 4、6周及 8周后血清sVCAM 1含量呈逐渐下降趋势 ,同用药前相比差异均有显著性 (P <0 0 5 ,P <0 0 1,P <0 0 1)。③B组和C组患者服药 4、6周及 8周后血浆TC含量与用药前相比差异均有统计学意义 (P <0 0 5 ,P <0 0 1,P <0 0 1)。④B组和C组患者血清sVCAM 1水平的降低与血浆TC含量的降低无明显相关性。 结论 辛伐他汀和普伐他汀不仅降低CHD患者血浆TC含量 ,而且降低血清中sV CAM 1的水平。

Objective To investigate the effects of simvastatin and pravastatin on the serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients with coronary heart disease (CHD). Methods Cases of 106 CHD patients were randomly divided into 3 groups: group A (given placebo), group B (treated with simvastatin), group C (administrated with pravastatin). The serum levels of sVCAM-1 and total cholesterol (TC) were measured by ELISA and enzyme assay, respectively. Results ① The serum levels of sVCAM-1 of group B and C were significantly lower than those of group A after having been treated for 4, 6 and 8 weeks. (P<0.05, P<0.01, P<0.01 respectively.) ② Both group B and group C were treated for 4, 6, 8 weeks, and their levels of sVCAM-1 were significantly lower than those before treatment (P<0.05, P<0.01, P<0.01 respectively). ③Group B and group C were treated for 4, 6 and 8 weeks, the levels of plasma TC were considerably lower than before (P<0.05, P<0.01, P<0.01 respectively.) ④ There was no significant correlation between the decrease of sVCAM-1 levels and that of TC in group B and C (P>0.05). Conclusions Both simvastatin and pravastatin not only decrease the levels of TC, but also reduce the expression of sVCAM-1.